Sight Sciences announces independent data on TearCare treatment

Sight Sciences reports independent data addressing a frequent question from eyecare practitioners and patients regarding the treatment of meibomian gland disease, MGD, using the TearCare System: How long does a single treatment last? Clinical outcomes for 78 dry eye patients treated at a single center, the Cleveland Eye Clinic, showcased the duration of efficacy of a single, first-time treatment of MGD using the TearCare System. Patients throughout the study exhibited improved dry eye signs and symptoms for more than 12 months, and in some cases up to 18 months, post treatment. Patients’ symptoms were assessed at a single time point pre-treatment and at four time points post-treatment. Patients treated with therapies other than TearCare within the 12-month window, including ophthalmic prescription medications, were excluded. In total, data from 78 patients who had been treated with the TearCare system and who returned for post-treatment follow up were included in the analysis. Results of the trial showed most subjects experienced at least 12 months of gland function improvement and decreased symptoms. Standard Patient Evaluation of Eye Dryness score data decreased approximately 6.2 points, from 14.1 +/- 6.5 to 7.9 +/- 5.7, at eight weeks after treatment and was maintained up to 12 months post-treatment, indicating a positive treatment outcome. In addition, the average meibomian gland expression score increased 4 points post-treatment from baseline of 4.9 +/- 2.6 in the right eye and 4.8 +/- 2.4 in the left eye to 9.0 +/- 2.7 in the right eye and 9.0 +/- 2.9 in the left eye nd remained at least 3 points higher from baseline over the course of a year with a month 12 score of 7.8 +/- 1.7 in the right eye and 7.8 +/- 1.4 in the left eye, again suggesting positive treatment outcomes in the signs of dry eye.